STOCK TITAN
  1. Home
  2. Sec-filings
  3. MGNX
  4. [Form 4] MACROGENICS INC Insider Trading Activity

MacroGenics (MGNX) SVP awarded RSUs, options and reports vesting

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

MacroGenics Inc. senior vice president Ezio Bonvini reported new equity awards and a vesting event. On February 12, 2026, he acquired 31,250 restricted stock units (RSUs) and 187,500 employee stock options, with the options carrying a $1.71 exercise price per share.

On February 15, 2026, 16,665 RSUs were converted into common stock, increasing his directly held common shares to 152,232 before related tax withholding. To cover taxes, 6,433 common shares were disposed of at $1.71 per share, leaving 145,799 common shares owned directly after these transactions.

Positive

  • None.

Negative

  • None.
Insider Bonvini Ezio
Role Sr VP, Research & CSO
Type Security Shares Price Value
Exercise Restricted Stock Unit 16,665 $0.00 --
Exercise Common Stock 16,665 $0.00 --
Tax Withholding Common Stock 6,433 $1.71 $11K
Grant/Award Restricted Stock Unit 31,250 $0.00 --
Grant/Award Employee Stock Option (right to buy) 187,500 $0.00 --
Holdings After Transaction: Restricted Stock Unit — 0 shares (Direct); Common Stock — 152,232 shares (Direct); Employee Stock Option (right to buy) — 187,500 shares (Direct)
Footnotes (1)
  1. On February 15, 2023, the reporting person was granted 50,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Restricted stock units convert into the Company's stock on a one-for-one basis. Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter. 12.5% of the shares underlying the grant became exercisable one year after the date of grant and an additional 6.25% of the shares underlying the grant became exercisable on the first day of each three-month period thereafter.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bonvini Ezio
(Last) (First) (Middle)
9704 MEDICAL CENTER DRIVE
(Street)
ROCKVILLE MD 20850
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MACROGENICS INC [ MGNX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Sr VP, Research & CSO
3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/15/2026 M 16,665 A (1) 152,232 D
Common Stock 02/15/2026 F 6,433 D $1.71 145,799 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit (1) 02/15/2026 M 16,665 (1) (1) Common Stock 16,665 $0 0 D
Restricted Stock Unit (2) 02/12/2026 A 31,250 (2) (2) Common Stock 31,250 $0 31,250 D
Employee Stock Option (right to buy) $1.71 02/12/2026 A 187,500 (3) 02/12/2036 Common Stock 187,500 $0 187,500 D
Explanation of Responses:
1. On February 15, 2023, the reporting person was granted 50,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date. Restricted stock units convert into the Company's stock on a one-for-one basis.
2. Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter.
3. 12.5% of the shares underlying the grant became exercisable one year after the date of grant and an additional 6.25% of the shares underlying the grant became exercisable on the first day of each three-month period thereafter.
Remarks:
/s/ Beth A. Smith, Attorney-in-fact 02/17/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did MacroGenics (MGNX) report for Ezio Bonvini?

MacroGenics (MGNX) reported that Ezio Bonvini, Sr VP Research & CSO, received new RSUs and stock options and had RSUs vest. He also disposed of some shares to cover tax obligations related to these equity awards, all held under direct ownership.

How many MacroGenics (MGNX) RSUs were granted to Ezio Bonvini?

Ezio Bonvini was granted 31,250 restricted stock units (RSUs) on February 12, 2026. Each RSU represents the right to receive one share of MacroGenics common stock, vesting in installments as described in the accompanying footnotes to the filing.

What stock options did Ezio Bonvini receive from MacroGenics (MGNX)?

On February 12, 2026, Ezio Bonvini received 187,500 employee stock options with an exercise price of $1.71 per share. These options relate to MacroGenics common stock and become exercisable over time according to the vesting schedule described in the footnotes.

How many MacroGenics (MGNX) RSUs vested and converted to common stock?

On February 15, 2026, 16,665 restricted stock units held by Ezio Bonvini were converted into MacroGenics common stock. This derivative conversion increased his directly owned common shares before taking into account shares disposed of for tax withholding.

Why did Ezio Bonvini dispose of MacroGenics (MGNX) shares in this Form 4?

The filing shows a disposition of 6,433 MacroGenics common shares at $1.71 per share using transaction code F. This indicates shares were withheld or delivered to satisfy tax liabilities associated with the equity award exercise or RSU vesting.

How many MacroGenics (MGNX) common shares does Ezio Bonvini own after these transactions?

Following the reported transactions, Ezio Bonvini directly owns 145,799 MacroGenics common shares. This figure reflects the RSU conversion into common stock and the share disposition used to cover related tax obligations described in the Form 4.

What is Ezio Bonvini’s role at MacroGenics (MGNX) in this insider filing?

In this filing, Ezio Bonvini is identified as an officer of MacroGenics with the title Senior Vice President, Research & Chief Scientific Officer. The equity awards and transactions reported relate to his position as a company executive, with all ownership listed as direct.